Anavex Life Sciences Corporation
AVXL
Market Cap$704.32M
Close$
$1.58
80.8% downside
Current Fair Value
80.8% downsideOvervalued by 80.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $704.32 Million |
|---|---|
| Enterprise Value | $584.37 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.52 |
| Beta | 0.82 |
| Outstanding Shares | 84,805,974 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -15.05 |
|---|---|
| PEG | -103.59 |
| Price to Sales | - |
| Price to Book Ratio | 8.25 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.65 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Anavex Life Sciences Corporation
CEO: Christopher Missling Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, ...